|
1
|
Nordal RR and Thoresen So: Uterine
sarcomas in Norway 1956-1992: Incidence survival and mortality. Eur
J Cancer. 33:907–911. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Oláh KS, Gee H, Blunt S, Dunn JA, Kelly K
and Chan KK: Retrospective analysis of 318 cases of uterine
sarcoma. Eur J Caner. 27:1095–1099. 1991. View Article : Google Scholar
|
|
3
|
Major FJ, Blessing JA, Silverberg SG,
Morrow CP, Creasman WT, Currie JL, Yordan E and Brady MF:
Prognostic factors in early-stage uterine sarcoma. Histopathology.
Cancer. 71((Suppl 4)): S1702–S1709. 1993. View Article : Google Scholar
|
|
4
|
Tropé CG, Abeler VM and Kristensen GB:
Diagnosis and treatment of sarcoma of the uterus. Histopathology.
Acta Oncol. 51:694–705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Powell MA, Filiac VL, Rose PG, Mannel RS,
Hanjani P, Degeest K, Miller BE, Susumu N and Ueland FR: Phase II
evaluation of paclitaxel and carboplatin in the treatment of
carcinosarcoma of the uterus, A Gynecologic Oncology Group study. J
Clin Oncol. 28:2727–2731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miller BE, Blessing JA, Stehman FB, Shahin
MS, Yamada SD, Secord AA, Warshal DP, Abulafia O, Richards WE and
Van Le L: A phase II evaluation of weekly gemcitabine and docetaxel
for second-line treatmentof recurrent carcinosarcoma of the uterus.
A Gynecologic Oncology Group study. Gynecol Oncol. 118:139–144.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoo HJ, Lim MC, Lim S, Park JY, Kang S,
Park SY and Seo SS: Phase II study of paclitaxel in combination
with carboplatin for patients with recurrent or persistent uterine
sarcoma. Arch Gynecol Obstet. 286:1529–1535. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gupta AA, Yao X, Verma S, Mackay H and
Hopkins L: Chemotherapy (gemcitabine, docetaxel plus gemcitabine,
doxorubicin, or trabectedin) in inoperable, locally advanced,
recurrent, or metastatic uterine leiomyosarcoma, A clinical
practice guideline. Curr Oncol. 20:e448–e454. 2012.
|
|
9
|
Bernstein-Molho R, Grisaro T, Soyfer V,
Safra T and Merimsky O: Metastatic uterine leiomyosarcomas, A
single-institution experience. Int J Gynecol Cancer. 20:255–260.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aghajanian C, Sill MW, Secord AA, Powell
MA and Steinhoff M: Iniparib plus paclitaxel and carboplatin as
initial treatment of advanced or recurrent uterine carcinosarcoma,
A Gynecologic Oncology Group study. Gynecol Oncol. 126:424–427.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hensley ML, Sill MW, Scribner DR Jr, Brown
J, Debernardo RL, Hartenbach EM, McCourt CK, Bosscher JR and Gehrig
PA: Sunitinib malate in the treatment of recurrent or persistent
uterine leiomyosarcoma: A Gynecologic Oncology Group phase II
study. Gynecol Oncol. 115:460–465. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gupta A, Yao X, Verma S, Mackay H and
Hopkins L: the Sarcoma Disease Site Group (DSG) and the Gynecology
Cancer DSG. Chemotherapy (i.e., gemcitabine, docetaxel plus
gemcitabine, doxorubicin, or trabectedin) for inoperable, locally
advanced, recurrent, or metastatic uterine leiomyosarcoma.
Evidence-based series. 11(11)2012.(Toronto, On). Cancer Care
Ontario, Program in Evidence-Based Care. 2012.
|
|
13
|
Olawaiye AB, Morgan JA, Goodman AK, Fuller
AF Jr and Penson RT: Epithelioid angiosarcoma of the uterus: A
review of management. Arch Gynecol Obstet. 278:401–404. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Homesley HD, Filiaci V, Markman M,
Bitterman P, Eaton L, Kilgore LC, Monk BJ and Ueland FR:
Gynecologic Oncology Group: Phase III trial of ifosfamide with or
without paclitaxel in advanceed uterine carcinosarcoma. A
Gynecologic Oncology Group study. Clin Oncol. 25:526–531. 2007.
View Article : Google Scholar
|
